Top Markets
#1 Black Phoenix Black Phoenix +355.57%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.07%
#4 Akedo Akedo +52.17%
#5 Acurast Acurast +34.63%
#6 BasedHype BasedHype +25.79%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.14%
#8 Cryptopia Cryptopia +21.54%
#9 Avantis Avantis +21.13%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +16.89%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Pathfinder Cell Therapy, Inc. Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy, Inc.

PFND
株式のランク #40886
Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in... Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.
株価
$0.0001
最終同期: 2026-08-12
時価総額
$66.72K
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Pathfinder Cell Therapy, Inc. (PFND)

カテゴリー

Healthcare
Pathfinder Cell Therapy, Inc.（PFND）の収益
Aug 2026 時点の収益 TTM: 0
Pathfinder Cell Therapy, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Pathfinder Cell Therapy, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE